Business Context and Reporting Period
Capstone Therapeutics Corp. (the filing entity; the request metadata refers to Capstone Holding Corp.) filed a Form 10-K for the fiscal year ended December 31, 2014. The company operated as a biotechnology development company with no revenue-generating products. Its principal activity was development of AEM-28 and related analogs through LipimetiX Development, LLC, a consolidated joint venture in which Capstone held a 60% common ownership interest and contributed $6.0 million.
The company had reduced operations to a virtual model with two full-time administrative employees and consultants. In 2014, it terminated the AZX100 license and returned the related intellectual property to the licensor. The joint venture completed its planned Phase 1a and Phase 1b/2a AEM-28 clinical trials during the fourth quarter.
Financial Results and Key Metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue-generating operations |
| General and administrative expense | $1.453 million | $1.169 million | Increased $284,000 |
| Research and development expense | $3.071 million | $3.124 million | Decreased $53,000 |
| Total operating expenses | $4.524 million | $4.293 million | Increased $231,000 |
| Interest and other expense, net | $43,000 expense | $158,000 income | Unfavorable swing of $201,000 |
| Income tax benefit | $400,000 | $21,000 | Higher Australian R&D credit |
| Net loss attributable to Capstone stockholders | $4.167 million | $3.921 million | Loss increased $246,000 |
| Basic and diluted loss per share | $0.10 | $0.10 | Reported amount unchanged |
| Cash used in operating activities | $4.094 million | $3.951 million | Use increased $143,000 |
| Cash and cash equivalents at year-end | $2.164 million | $6.258 million | Decreased $4.094 million |
| Total assets | $3.385 million | $7.317 million | Decreased $3.932 million |
| Total current liabilities | $282,000 | $100,000 | Increased $182,000 |
| Total equity | $3.103 million | $7.217 million | Decreased $4.114 million |
Because the company had no revenue, gross margin and operating margin are not meaningful. The operating loss before taxes was $4.567 million. No debt financing or financing cash flows were reported. The company had $500,000 outstanding under a revolving loan agreement advancing funds to the joint venture, with the net amount due June 30, 2015; the agreement permitted advances up to $700,000 net of expected tax credits or other funds.
At December 31, 2014, the company reported approximately $57 million of deferred tax assets subject to a full valuation allowance, including approximately $146 million of federal and $33 million of state net operating loss carryforwards and approximately $6 million of research and development and alternative minimum tax credits.
Material Changes Versus the Prior Comparable Period
- Net loss attributable to Capstone stockholders increased from $3.921 million to $4.167 million, primarily reflecting higher general and administrative costs, the loss of 2013's $152,000 insurance-related income, and a $120,000 foreign exchange loss related to Australian activities.
- General and administrative expense increased 24%, driven principally by qui tam litigation and investor-relations costs.
- Research and development expense declined modestly, while the joint venture's initial development program was substantially completed.
- Operating cash use increased to $4.094 million, reducing year-end cash by approximately 65% to $2.164 million.
- The Australian subsidiary recorded refundable research and development tax credits of AUD$227,000 for the period ended June 30, 2014 and AUD$242,000 for the period ended December 31, 2014; the consolidated income tax benefit reported for 2014 was $400,000.
- AEM-28 Phase 1a and Phase 1b/2a trials in Australia enrolled 36 and 15 patients, respectively, and were completed in 2014. The company reported a generally acceptable safety profile and statistically significant pharmacodynamic results favoring AEM-28 on multiple lipid biomarkers in pooled data.
- The company terminated the AZX100 license and returned all related rights to the licensor.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management planned to maintain a limited virtual operating model in 2015, focused on monitoring and participating in the joint venture and meeting public-company reporting and governance requirements. Additional material development of AEM-28 and its analogs was not expected without new funding. The company intended to pursue fundraising, partnering, licensing, or other strategic alternatives.
The independent auditor reported substantial doubt about the company's ability to continue as a going concern because additional funding was needed to continue operations and develop AEM-28 and its analogs. Management stated that failure to obtain funding could impair both the joint venture's development program and the company's ability to continue as a going concern.
- The unresolved qui tam False Claims Act litigation relates to the former bone-growth-stimulation business sold in 2003. The government declined to intervene, discovery was open, and no trial date had been set. The claimed damages, including potential statutory penalties and treble damages, could exceed the company's financial resources. No material loss was accrued because management did not believe a material loss was probable and estimable.
- If the joint venture or company cannot continue as a going concern, Capstone could incur an additional loss of up to approximately $667,000 relating to losses allocated to noncontrolling interests. The company also identified approximately $932,000 of net joint venture investment and revolving loan exposure.
- AEM-28-02 remained at the preclinical stage. Neither AEM-28 nor its analogs had regulatory approval or commercial sales, and further trials would require regulatory approvals and substantial additional capital.
- Patent license rights were carried at $666,000 net at year-end after $379,000 of accumulated amortization. Their future value depended on obtaining funding or completing a sale, licensing, or other strategic transaction.
- The company had 3.023 million outstanding stock options with a weighted-average exercise price of $1.06, plus warrants to purchase 164,129 shares. Potential future equity financing and option or warrant exercises could dilute existing stockholders.
- A Tax Benefit Preservation Plan adopted in June 2014 designated 1 million shares of Series A preferred stock and could delay or prevent a change in control; the plan expires June 24, 2016.
Most Important Facts to Verify
- Confirm the legal registrant name: the supplied filing is for Capstone Therapeutics Corp., not Capstone Holding Corp.
- Verify the reported $2.164 million cash balance against the company's ongoing cash burn, the $500,000 joint venture advance due June 30, 2015, and any subsequent financing.
- Review subsequent developments involving the going-concern qualification, strategic alternatives, and the continuation or termination of AEM-28 development.
- Check the status, expected exposure, and any settlement or judgment in the qui tam litigation.
- Validate the clinical-trial safety and efficacy findings using complete trial reports; the filing describes early, first-in-human studies and does not establish regulatory approval or commercial viability.
- Assess the recoverability of the joint venture investment, patent license rights, and tax attributes, including the full valuation allowance on deferred tax assets.
- Review potential dilution from outstanding options, warrants, preferred-stock authority, and any future capital raising.